Overview Sitravatinib in Metastatic Breast Cancer Status: Recruiting Trial end date: 2026-02-01 Target enrollment: Participant gender: Summary This study evaluates the efficacy of sitravatinib in patients with metastatic breast cancer. All study participants will receive sitravatinib, 120 mg daily, until their cancer worsens, or until they develop intolerable side effects. Phase: Phase 2 Details Lead Sponsor: Maryam Nemati ShafaeeCollaborator: Mirati Therapeutics Inc.